(Q51028676)

27 March 2018

title

Immunologic parameters and viral infections in patients desensitized with intravenous immunoglobulin and rituximab. (English)

1 reference

27 March 2018

12

Stanley C Jordan

1 reference

27 March 2018

author name string

Shili Ge

1

1 reference

27 March 2018

Andy Pao

2

1 reference

27 March 2018

Ashley Vo

3

1 reference

27 March 2018

Nathan Deer

4

1 reference

27 March 2018

Artur Karasyov

5

1 reference

27 March 2018

Anna Petrosyan

6

1 reference

27 March 2018

Joseph Kahwaji

7

1 reference

27 March 2018

Marina Lukovsky

8

1 reference

27 March 2018

Ning-Ning Chai

9

1 reference

27 March 2018

Angela Aguiluz

10

1 reference

27 March 2018

James Mirocha

11

1 reference

27 March 2018

Mieko Toyoda

13

1 reference

27 March 2018

publication date

28 November 2010

1 reference

27 March 2018

published in

Transplant Immunology

1 reference

27 March 2018

volume

24

1 reference

27 March 2018

issue

3

1 reference

27 March 2018

page(s)

142-148

1 reference

27 March 2018

Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Rituximab and intravenous immune globulin for desensitization during renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Rituximab as treatment for refractory kidney transplant rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Rituximab in highly sensitized kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Impact of rituximab therapy for treatment of acute humoral rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Incidence of JC-virus replication after rituximab therapy in solid-organ transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

The AJT report: news and issues that affect organ and tissue transplantation. Wrestling with positive cross-matches. A look at some of the newer desensitization therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Cellular immune responses to cytomegalovirus in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Co-infection of polyomavirus-BK and cytomegalovirus in renal transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Clinical significance of peripheral blood Epstein-Barr viral load monitoring using polymerase chain reaction in renal transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Campath-1H induction and the incidence of infectious complications in adult renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Human natural killer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

10.1016/J.TRIM.2010.11.006

7 January 2021

Identifiers

DOI

1 reference

27 March 2018

1 reference

27 March 2018